Insider Selling: Gilead Sciences, Inc. (GILD) Insider Sells $6,054,372.48 in Stock
Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.56, for a total value of $6,054,372.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at 82.14 on Friday. The firm has a market cap of $107.27 billion, a price-to-earnings ratio of 8.92 and a beta of 1.14. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The company’s 50 day moving average is $80.97 and its 200 day moving average is $71.66.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the prior year, the business posted $3.08 EPS. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post $8.75 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
TRADEMARK VIOLATION WARNING: “Insider Selling: Gilead Sciences, Inc. (GILD) Insider Sells $6,054,372.48 in Stock” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/insider-selling-gilead-sciences-inc-gild-insider-sells-6054372-48-in-stock/1614241.html.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Parnassus Investments CA grew its stake in Gilead Sciences by 37.4% in the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Gilead Sciences by 9.8% in the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Renaissance Technologies LLC grew its stake in Gilead Sciences by 35.0% in the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after buying an additional 2,700,600 shares during the last quarter. Vanguard Group Inc. grew its stake in Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Gilead Sciences by 50.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after buying an additional 2,062,886 shares during the last quarter. Institutional investors own 73.99% of the company’s stock.
A number of equities analysts recently issued reports on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Jefferies Group LLC reissued a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Tuesday, July 4th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a report on Monday, July 17th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price target on the stock. in a report on Wednesday, June 21st. Finally, Deutsche Bank AG started coverage on Gilead Sciences in a report on Friday, June 23rd. They set a “buy” rating and a $79.00 price target on the stock. Twelve investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $85.66.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.